ストックスクリーナーアプリを入手
0.3621
6.70%
-0.0259
前日終値:
$0.388
開ける：
$0.3857
24時間の取引高:
182.12K
Relative Volume:
0.58
時価総額：
$16.85M
収益：
$106.79M
当期純損益:
$-8.73M
株価収益率:
-1.8105
EPS:
-0.2
ネットキャッシュフロー:
$10.81M
1週間 パフォーマンス:
-8.54%
1か月 パフォーマンス:
-43.09%
6か月 パフォーマンス:
-84.73%
1年 パフォーマンス:
-90.22%
1日の値動き範囲:
$0.362
$0.40
1週間の範囲:
$0.362
$0.4537
52週間の値動き範囲:
$0.355
$4.08
Harvard Bioscience Inc Stock (HBIO) Company Profile
名前
Harvard Bioscience Inc
セクター
電話
(508) 893-8999
住所
84 OCTOBER HILL RD, HOLLISTON, MA
HBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
0.3621 | 16.85M | 106.79M | -8.73M | 10.81M | -0.20 |
|
ISRG
Intuitive Surgical Inc
|
464.61 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
194.00 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
90.92 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
210.06 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
78.55 | 15.83B | 3.90B | 392.30M | 288.10M | 1.95 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-09 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-03-10 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2021-01-07 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-09 | 開始されました | Northland Capital | Outperform |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2019-07-08 | ダウングレード | Janney | Buy → Neutral |
| 2018-01-24 | 繰り返されました | Janney | Buy |
| 2018-01-23 | 繰り返されました | The Benchmark Company | Buy |
| 2016-11-17 | 開始されました | Singular Research | Buy |
| 2015-07-28 | 開始されました | The Benchmark Company | Buy |
すべてを表示
Harvard Bioscience Inc (HBIO) 最新ニュース
Harvard Bioscience’s Bertrand Loy to Step Down - TipRanks
Benchmark reiterates Harvard Bioscience stock with $4.50 target By Investing.com - Investing.com India
Harvard Bioscience’s (HBIO) Sector Weight Rating Reiterated at KeyCorp - Defense World
Harvard Bioscience (HBIO) Announces CFO Transition - GuruFocus
Harvard Bioscience Announces CFO Transition | HBIO Stock News - GuruFocus
Harvard Bioscience (HBIO) Sees CFO Transition with Interim Appoi - GuruFocus
Lacklustre Performance Is Driving Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 49% Price Drop - simplywall.st
Harvard Bioscience Appoints Mark Frost as Interim CFO - citybiz
Harvard Bioscience appoints interim CFO amid market challenges By Investing.com - Investing.com Canada
Harvard Bioscience CFO Jennifer Cote Resigns - marketscreener.com
Harvard Bioscience CFO Resignation and Interim Appointment - TipRanks
Harvard Bioscience appoints interim CFO amid market challenges - Investing.com
Harvard Bioscience Announces CFO Transition - The Manila Times
KeyBanc cuts Harvard Bioscience stock rating on financing risk By Investing.com - Investing.com Canada
Estimating The Fair Value Of Harvard Bioscience, Inc. (NASDAQ:HBIO) - Yahoo Finance
KeyBanc Downgrades Harvard Bioscience to Sector Weight From Overweight, Removes $3 Price Target - marketscreener.com
KeyBanc cuts Harvard Bioscience stock rating on financing risk - Investing.com
Harvard Bioscience Slides As Insider Purchases Lose Another US$76k - simplywall.st
Harvard Bioscience (NASDAQ:HBIO) Price Target Cut to $4.50 by Analysts at Benchmark - Defense World
Harvard Bioscience at 37th Annual ROTH Conference: Strategic Growth Amid Challenges By Investing.com - Investing.com South Africa
Harvard Bioscience at 37th Annual ROTH Conference: Strategic Growth Amid Challenges - Investing.com
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2024 Earnings Call Transcript - Insider Monkey
Harvard Bioscience Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Harvard Bioscience Inc (HBIO) Q4 2024 Earnings Call Highlights: - GuruFocus.com
Harvard Bioscience Inc (HBIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Harvard Bioscience Reports 2024 Financial Results - TipRanks
Harvard Bioscience Navigates Growth Amid Challenges - TipRanks
Harvard Bioscience secures waiver for credit covenant By Investing.com - Investing.com Australia
Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025 - GlobeNewswire
Harvard Bioscience CEO to Host Fireside Chats at Roth and KeyBanc Healthcare Forums - StockTitan
Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Earnings call transcript: Harvard Bioscience Q4 2024 beats expectations but faces market challenges - Investing.com
Harvard Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Harvard Bioscience slumps after weak revenue forecast - TradingView
HARVARD BIOSCIENCE Earnings Results: $HBIO Reports Quarterly Earnings - Nasdaq
Harvard Bioscience reports Q4 adjusted EPS 6c vs. 4c last year - TipRanks
Harvard Bioscience earnings beat, revenue topped estimates By Investing.com - Investing.com UK
Harvard Bioscience Achieves Profit Turnaround Despite Revenue Challenges in Latest Quarter - StockTitan
Harvard Bioscience IncQ4 2024 Revenues $24.6 Million -March 12, 2025 at 07:04 am EDT - Marketscreener.com
Harvard Bioscience Q4 and Full-Year 2024 Financial Results - TradingView
Harvard Bioscience secures waiver for credit covenant - Investing.com
Harvard BioscienceExploring Alternative Capital Sources For Refinancing Outstanding Indebtedness By June 30 - Marketscreener.com
Costco Price Plunge Equals Opportunity for Investors - The Globe and Mail
Harvard Bioscience (HBIO) Expected to Announce Earnings on Wednesday - The AM Reporter
Harvard Bioscience, Inc. to Host Earnings Call - ACCESS Newswire
HBIO stock touches 52-week low at $0.86 amid market challenges - Investing.com Australia
Harvard Bioscience Inc (HBIO) 財務データ
収益
当期純利益
現金流量
EPS
0.66%
0.58%
大文字化:
|
ボリューム (24 時間):